News

News

WIB_icon

Sequential Pembrolizumab and Chemotherapy Results in Excellent Responses in Newly Diagnosed Classical Hodgkin Lymphoma

A brief course of pembrolizumab monotherapy followed by AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) was associated with reductions in metabolic tumor volume and prolonged...
WIB_icon

Is Post-Discharge VTE Prophylaxis Necessary for Patients With COVID-19?

In hospitalized patients with COVID-19, the risk of venous thromboembolism (VTE) following discharge was not significantly greater compared with the VTE risk in patients...

Oliceridine Approved for Management of Acute Pain

Oliceridine, a parenterally administered μ-receptor opioid agonist, is approved for the management of moderate to severe acute pain in adults requiring an intravenous (IV)...

New “Buy American” Order Mandates Domestic Manufacturing of Essential Drugs

President Donald Trump signed a new executive order requiring that certain “essential” drugs and medical supplies purchased by the federal government be manufactured in...

FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin-blmf, an anti–B-cell maturation antigen (BCMA) antibody-drug conjugate therapy, received accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma...

Tafasitamab-cxix Receives Accelerated Approval for Relapsed/Refractory DLBCL

The FDA granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma...

The Year in FDA Approvals

Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...
Sickle cell anemia

Hydroxyurea Treatment Before Puberty Does Not Impair Future Sperm Quality in Boys With SCD

Childhood hydroxyurea (hydroxycarbamide) treatment does not impair future sperm parameters in boys with severe sickle cell disease (SCD), according to research published in Blood....

Tranexamic Acid for Gastrointestinal Bleeding: Time to HALT-IT?

Although tranexamic acid reduces the risks of surgical bleeding and bleeding-related death in patients with trauma, it does not reduce risk of death from...
WIB_icon

Mavorixafor Mobilizes White Blood Cells in Patients With WHIM Syndrome

Long-term treatment with once-daily oral mavorixafor, an inhibitor of CXCR4, reduced the number of cutaneous warts and infections and effectively increased neutrophil and lymphocyte...
Advertisement

Current Issue

October 2020 Volume 6, Issue 12

This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.

Block title